VSTM Wutah dodolan triwulanan Verastem Corp

Simbol resmi perusahaan verastem.com (VSTM)

The development of targeted drugs is independent of economic cycles, relying solely on biological risks. The QoQ revenue growth rate demonstrates current volatility, with the value recorded at 114.10. The future of Verastem, Inc. (VSTM) is determined by FDA verdicts on the inhibitor avutometinib and cash runway management. The fate of this biotech ecosystem, which lacks a commercial base, is entirely dependent on the approval of its ovarian cancer therapy.

VSTM (Verastem Oncology) riwayat Tingkat wutah pendapatan sajrone kuartal saka 04.07.2022 nganti 20.11.2026

Rincian analitis perusahaan Verastem Inc (VSTM)

- rega saham lan target rega konsensus:
Ringkesan analitik perusahaan:Verastem, Inc. (VSTM)
Barang unggulan Verastem Oncology

For the biotech company Verastem, Inc. (VSTM), which is advancing targeted oncology by recruiting leading biochemists, the quarterly sales growth rate reflects the efficiency of commercializing scientific research. This metric compares current revenue with the same period of the previous cycle, allowing investors to promptly identify revenue stagnation or expansion phases to timely adjust portfolios and protect capital from market risks.